Search
Tanaproget
go.drugbank.com/drugs/DB04787ExperimentalIt is a high affinity, high efficacy agonist of the progesterone receptor (PR) with a much more selective binding profile relative to most conventional progestins. … Because of this tanaproget may prove to produce fewer side effects in comparison. It is currently in the process of being developed for clinical use as a contraceptive by Ligand Pharmaceuticals.
Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-RingMCC
go.drugbank.com/drugs/DB05282InvestigationalMCC has been shown to have immune stimulatory and apoptosis (programmed cell death) activity against cancer cells. The product is a sterile biological composition in a sub-micron suspension. … It is produced at the Bioniche manufacturing facility in Pointe-Claire, Quebec.
Dapansutrile
go.drugbank.com/drugs/DB16130InvestigationalDapansutrile is under investigation in clinical trial NCT01768975 (Phase 2 Efficacy Trial of OLT1177 Gel in Subjects With Moderate to Severe Pain Associated With OA of the Knee).
ALGRX 1207
go.drugbank.com/drugs/DB06482ExperimentalALGRX 1207 is a topical local anesthetic that acts by binding to the fast sodium channel. … ALGRX 1207 entered clinical trials for cutaneous neuropathic pain, such as chemotherapy-induced neuropathy, in 2006. It was being developed by Anesiva, but trials have halted.
PN0621
go.drugbank.com/drugs/DB05218ExperimentalPN0621 is an anti-TNF, domain antibody (dAb) based therapeutic. It targets tumour necrosis factor (TNF) to treat auto-immune inflammatory diseases such as rheumatoid arthritis. … It is being developed by Peptech.
Jojoba oil
go.drugbank.com/drugs/DB14252ApprovedJojoba oil is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Mixtures: Anbiser B-HA Hyaluronic Acid Nourishing ConditionerScutellaria lateriflora
go.drugbank.com/drugs/DB14339ApprovedScutellaria lateriflora is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Cobitolimod
go.drugbank.com/drugs/DB14819InvestigationalCobitolimod is under investigation in clinical trial NCT03178669 (The Efficacy of Cobitolimod in Patients With Moderate to Severe Active Ulcerative Colitis).
KAHR-102
go.drugbank.com/drugs/DB17427InvestigationalKAHR-102 is a dual signaling protein fusing cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) to the Fas-ligand (FasL).
HMI-103
go.drugbank.com/drugs/DB17684InvestigationalHMI-102 is an investigational gene therapy designed to encode the phenylalanine-4-hydroxylase (PAH) gene, mutated in people with phenylketonuria.